Comparing Fluconazole and Clotrimazole in treatment of candida albicans vaginitis

Author(s):
NS Karimaan NS Karimaan 1,*, Z ShafaaiiZ Shafaaii1, M Afraakhte M Afraakhte 1, N Valaaii N Valaaii 1, M AhmadiM Ahmadi1
1Iran
*Corresponding Author: Corresponding author: NS Karimaan , Iran, E-mail: Email: [email protected]

Journal of Kermanshah University of Medical Sciences:Vol. 6, issue 3; e81013
Published online:Dec 19, 2002
Article type:Research Article
Received:Aug 12, 2002
Accepted:Dec 11, 2002
How to Cite:Karimaan N, Shafaaii Z, Afraakhte M, Valaaii N, Ahmadi M. Comparing Fluconazole and Clotrimazole in treatment of candida albicans vaginitis. J Kermanshah Univ Med Sci. 2002;6(3):e81013. doi:

Abstract

Introduction and Objectives: This study was done to compare the effectiveness of  Fluconazole and Clotrimazole in treatment of candida albicans vaginitis in patients referring to health centers affiliated with Shahid Beheshti University, during the year 1379.

 Materials and Methods: 70 patients received either a single oral dose of 150 mg Fluconazole (35 patients)  or  7 days course of vaginal Clotrimazole. Clinical history, smear, and culture  were  obtained.

Results: Positive Clinical and laboratory response was seen in 77% and 74% and 91% and 77% of Fluconazole and Clotrimazole groups, respectively. There was no statistically significant differences between the 2 groups regarding clinical or laboratory responses to treatment.

Discussion and Conclusions: If confirmed by others, a single oral dose of 150 mg Fluconazole should replace the  7 days course of vaginal Clotrimazole.

Fulltext

The full text of this article is available on PDF

Copyright

© 2002, Journal of Kermanshah University of Medical Sciences. This open-access article is available under the Creative Commons Attribution-NonCommercial 4.0 (CC BY-NC 4.0) International License (https://creativecommons.org/licenses/by-nc/4.0/), which allows for the copying and redistribution of the material only for noncommercial purposes, provided that the original work is properly cited.

Similar Articles

30
Sep
2000

‌Treatment and recurrence of vaginal candidiasis after oral and intravaginal treatment

M Khorsandi,
M Modares Gilani,
AR Khosravi

Khorsandi M, Modares Gilani M, Khosravi A. ‌Treatment and recurrence of vaginal candidiasis after oral and intravaginal treatment. J Inflamm Dis. 2024;4(2):e154708. doi:

31
Jan
2007

Vaginal azoles Versus oral Fluconazole in Treatment of Recurrent Vulvovaginal Candidiasis

Zahra Fardyazar,
Shahram Habibzadeh,
Sedigheh Abdollahi Fard,
Mahshid Tello

Fardyazar Z, Habibzadeh S, Abdollahi Fard S, Tello M. Vaginal azoles Versus oral Fluconazole in Treatment of Recurrent Vulvovaginal Candidiasis. Arch Clin Infect Dis. 2007;2(1):. doi:

9
Sep
2012

Sensitivity of Vaginal Isolates of Candida to Eight Antifungal Drugs Isolated From Ahvaz, Iran

Zahra Salehei,
Zahra Seifi,
Ali Mahmoudabadi

Salehei Z, Seifi Z, Mahmoudabadi A. Sensitivity of Vaginal Isolates of Candida to Eight Antifungal Drugs Isolated From Ahvaz, Iran. Jundishapur J Microbiol. 2012;5(4):574-577. doi: https://doi.org/10.5812/jjm.4556

28
Jun
2021
Arch Clin Infect Dis

Azole Antifungal Resistance in Candida albicans and Candida glabrata Isolated from Vulvovaginal Candidiasis Patients

Niloofar Deravi,
Mobina Fathi,
Seyede Nadia Tabatabaeifar,
Parichehr Pooransari,
Bahram Ahmadi,
Gholamreza Shokoohi
,et al.

Deravi N, Fathi M, Tabatabaeifar SN, Pooransari P, Ahmadi B, et al. Azole Antifungal Resistance in Candida albicans and Candida glabrata Isolated from Vulvovaginal Candidiasis Patients. Arch Clin Infect Dis. 2021;16(2):e106360. doi: https://doi.org/10.5812/archcid.106360

20
Nov
2010

Effectiveness of Fluconazole for Suppressive Maintenance Therapy in Patients with RVVC: a Randomized Placebo-Controlled Study

Forouzan Bolouri,
Nasrin Moghadami Tabrizi,
Fatemeh Davari Tanha,
Azra Azmoodeh,
Saeed Emami,
Mehraban Falahati
,et al.

Bolouri F, Moghadami Tabrizi N, Davari Tanha F, Azmoodeh A, Emami S, et al. Effectiveness of Fluconazole for Suppressive Maintenance Therapy in Patients with RVVC: a Randomized Placebo-Controlled Study. Iran J Pharm Res. 2022;8(4):e128654. doi: https://doi.org/10.22037/ijpr.2010.827

Download PDF229.46 KB
Share on
Cited by
Metrics

Ordering Reprints

Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC 

Search Relations

Author(s):

Related Articles